A Randomized, Double-Blind, Active-Comparator Controlled, Clinical Trial to Study the Efficacy and Safety of MK0431A [sitagliptin/metformin] for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM).
Phase of Trial: Phase III
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Metformin/sitagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck & Co
- 10 Jun 2017 Biomarkers information updated
- 01 Jul 2011 Results published in the Diabetes, Obesity and Metabolism.
- 18 Oct 2009 Results presented at the 20th World Diabetes Congress (WDC).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History